Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial

Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?

“…Studies available in the literature so far, involving more than 2600 patients (Begueria et al, 2019;Chen et al, 2017;Dong et al, 2017;Kuang et al, 2015;Wang et al, 2016b;Yu et al,2018;Zhu et al, 2015Zhu et al, , 2017aZhu et al, , 2017b, are summarized in TABLE 2. The first study on the use of a progestin during ovarian stimulation was published by colleagues in 2015 (Kuang et al, 2015).…”

“…Some inconsistencies have been reported regarding reproductive outcomes with the use of MPA. A recent trial (Begueria et al, 2019) aimed to evaluate the non-inferiority of MPA compared with a GnRH antagonist on the number of mature oocytes retrieved in oocyte donation cycles. This large trial was conducted on 252 oocyte donors, of whom 173 reached oocyte retrieval, and reported no differences in length of ovarian stimulation, dose of gonadotrophin needed, endogenous hormonal profile or number of mature oocytes between women treated with MPA or a GnRH antagonist.…”

Dydrogesterone‐primed ovarian stimulation is an effective alternative to gonadotropin‐releasing hormone antagonist protocol for freeze‐all cycles in polycystic ovary syndrome

“…15 Begueria et al performed a non-inferiority trial to compare MPA and GnRH antagonist with regard to the number of mature oocytes retrieved in oocyte donation cycles, and reported no differences in the number of mature oocytes, length of stimulation, fertilization rate, or quality of embryos between the two treatments. 30 Although pregnancy rates were lower in the MPA group, live birth rates were similar between the two groups. 30 Recently, Yildiz et al compared a novel flexible PPOS protocol with the antagonist protocol in oocyte donation cycles.…”

“…30 Although pregnancy rates were lower in the MPA group, live birth rates were similar between the two groups. 30 Recently, Yildiz et al compared a novel flexible PPOS protocol with the antagonist protocol in oocyte donation cycles. In their study, MPA was started on stimulation day 7 or when the leading follicle reached 14 mm in diameter.…”

“…Interestingly, a few studies have also compared the antagonist protocol with PPOS. 15,30,31 Iwami et al compared the antagonist protocol and PPOS and obtained similar results in normo-responsive patients. 15 Begueria et al performed a non-inferiority trial to compare MPA and GnRH antagonist with regard to the number of mature oocytes retrieved in oocyte donation cycles, and reported no differences in the number of mature oocytes, length of stimulation, fertilization rate, or quality of embryos between the two treatments.…”